MORRIS PLAINS, N.J., Nov. 07, 2018 (GLOBE NEWSWIRE) — Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced its current clinical collaboration with AstraZeneca (NYSE: AZN) and MedImmune for the development of Imfinzi® (durvalumab) and sacituzumab govitecan combination therapy has been broadened to include second-line …
Tag Archives: Sacituzumab Govitecan
November, 2018
July, 2018
-
18 July
FDA Grants Priority Review to Immunomedics’ Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer
MORRIS PLAINS, N.J., July 18, 2018 (GLOBE NEWSWIRE) — Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Biologics License Application (BLA) for filing and granted Priority Review …
January, 2018
-
12 January
Immunomedics Enters Agreement with University of Wisconsin to Expand Sacituzumab Govitecan into Prostate Cancer
MORRIS PLAINS, N.J., Jan. 11, 2018 (GLOBE NEWSWIRE) — Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced a collaboration with the Carbone Cancer Center at the University of Wisconsin, through Immunomedics entering an agreement with The Prostate Cancer Clinical Trials Consortium (PCCTC), to investigate Immunomedics’ lead antibody-drug conjugate (ADC) product candidate, …
May, 2017
-
5 May
Seattle Genetics Terminates License Agreement with Immunomedics
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that it has agreed to terminate its license agreement with Immunomedics, Inc. (Nasdaq: IMMU) for sacituzumab govitecan (IMMU-132) and settle the related litigation. The license agreement had not yet closed due to legal action brought by an …
April, 2017
-
5 April
Immunomedics’ Lead ADC is Active in Patients with Metastatic Small-Cell Lung Cancer
Washington, D.C., April 5, 2017 — Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or “the Company”) today reported that sacituzumab govitecan (IMMU-132), the Company’s lead antibody-drug conjugate (ADC), has activity and manageable toxicity in patients with advanced and heavily-pretreated metastatic small-cell lung cancer (SCLC). “Despite recent progress in immunotherapy and the identification …
February, 2017
-
10 February
Immunomedics in up to $2 Billion License Agreement with Seattle Genetics for Sacituzumab Govitecan
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced a development and license agreement with Immunomedics, Inc. (Nasdaq: IMMU) under which Seattle Genetics would receive exclusive worldwide rights to develop, manufacture and commercialize sacituzumab govitecan (IMMU-132). Sacituzumab govitecan is an antibody-drug conjugate (ADC) targeted to TROP-2, …
February, 2016
-
8 February
Immunomedics’ TNBC Drug Receives Breakthrough Therapy Designation from the FDA
Morris Plains, NJ, February 5, 2016 — Immunomedics, Inc., (Nasdaq: IMMU) today announced that its lead investigational antibody-drug conjugate, sacituzumab govitecan, or IMMU-132, has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer (TNBC) who have failed at least 2 prior therapies for …